Brooklyn ImmunoTherapeutics : SNN Network Summer Virtual Event Presentation

A platform company in cell, gene-editing & cytokine therapies

Next Generation

Personalized

Medicines

SNN Network Summer Virtual Event August 18, 2021

Disclaimer

This presentation is intended to provide summary information about the business of Brooklyn ImmunoTherapeutics LLC ("BTX" or the "Company"). The information in this presentation is in no respects complete, comprehensive, or exhaustive, and reference is made to the proxy statement/prospectus/consent solicitation statement of NTN Buzztime, Inc.dated February 8, 2021, which has been filed by NTN with the U.S. Securities and Exchange Commission.

This presentation is not an offer to sell securities nor should it be deemed to imply an offer of securities.

This presentation, among other matters, contains forward-looking statements based on estimates and assumptions. Forward-looking statements include information concerning possible or assumed future results of operations of the Company, and possible future financing, partnering, strategic, sale or other transaction(s) and other information relating to the Company. Forward-looking statements include statements containing the words "believes," "plans," "hopes," "expects," "anticipates," "intends," "estimates" or other similar words or expressions. Except for the historical information contained herein, the matters discussed are forward-looking statements. Forward-looking statements involve significant known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any actual future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason. These statements involve risks and uncertainties as to which the Company can provide no assurances. No assurance can be given that the Company will succeed in consummating any commercial relationship or transaction or the terms and conditions upon which any such relationship or transaction may be consummated. Further,

a number of factors including (i) the impact of the ongoing COVID-19 pandemic on the timeline for the Company's clinical trials and on the Company's business activities generally, (ii) the Company's ability to complete its clinical trials on a timely basis and within the budgets for such trials, (iii) whether the clinical trials undertaken or will undertake in the future will be successful, (iv) whether the Company's API manufacturing operations can maintain compliance with current Good Manufacturing Practices, (v) the scope of the Company's intellectual property protections and the outcome of any future challenges or opposition to the Company's intellectual property, (vi) whether the Company's future efforts to acquire or in-license complementary programs will prove successful, (vii) whether the Company's efforts to pursue partnerships to advance and accelerate clinical programs will prove successful, (viii) whether the Company's merger with NTN will be completed, (ix) whether the Company will be able to successfully list the common stock of the combined company on the NYSE American following the merger, and (x) the other factors described in the "Risk Factors" section of the Registration Statement, could adversely affect the Company. Further, market and industry statistics contained in this presentation are based on information available to us. While we believe that information to be accurate, it was not prepared for purposes of a securities offering or economic analysis.

All forward looking statements speak only as of the date hereof and except as required by law, the Company assumes no obligation to update these forward-looking statements even if new information becomes available.

2

Brooklyn ImmunoTherapeutics

A platform company in cell, gene-editing and cytokine therapies

Clinical stage

Cytokine therapy

Nucleic acid delivery

Cell reprogramming

Gene editing

3

Brooklyn ImmunoTherapeutics (BTX) - Overview

Broad portfolio including a Phase 2b cytokine asset, potential for additional cytokine compounds, and an exclusive license for a multi product gene editing and cell therapy platform

• Strong and efficient leadership team with >50 years in drug development/healthcare
• GMP Manufacturing Facility with capabilities on both sides of the company

Cytokine Therapies

IRX-2:

• Ongoing Phase 2b study in Neoadjuvant Head and Neck Cancer
• Additional Investigator Sponsored Studies in various tumor types (including combinations with Checkpoint Inhibitors)
• 3 independent human studies showing increases in numbers and types of immune cells after treatment with IRX-2

mRNA-based Gene Editing

and Cell Therapies

Exclusive license for a broad mRNA technology platform:

• mRNA cell reprogramming (cell therapy)
• mRNA-basedgene editing
• Proprietary gene editing protein
• Proprietary lipid delivery system

4

BTX is Led by a Strong, Experienced Management Team

Howard Federoff		Kevin D'Amour		Ron Guido		Lynn Sadowski Mason		Jay Sial
MD, PhD		PhD		MS, MS Pharm. Med.		MS		MBA
Chief Executive Officer		Chief Scientific Officer		Chief Development		EVP, Clinical		Chief Administrative
and President				Officer		Operations		Officer

• Sention Inc.

• Therapeutic

Management

5